EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers

Elizabeth C Smyth,1,2 Georgios Vlachogiannis1,3,4 Somaieh Hedayat,3,4 Alice Harbery,5 Sanna Hulkk-Wilson,3 Massimiliano Salati,3,4 Kyriakos Kouvelakis,6 Javier Fernandez-Mateos,4 George D Cresswell1,4 Elisa Fontana,3 Therese Seidtitz,7 Clare Peckitt,5 Jens C Hahne,3,4 Andrea Lampis,3,4 Ruwaida Begum,2 David Watkins,2 Sheela Rao,2 Naureen Starling,2 Tom Waddell,2,8 Alicia Okines,7 Tom Crosby,9 Was Mansoor,8 Jonathan Wadsley,10 Gary Middleton,11 Matteo Fassan,12 Andrew Wotherspoon,13 Chiara Braconi,5,7,14 Ian Chau,2 Igor Vivanco,5 Andrea Sottoriva,4 Daniel E Stange7,15,16 David Cunningham,2 Nicola Valeri1,2,3,4

Objective

EGFR amplification may be effective in biomarker-selected populations of advanced gastro-oesophageal adenocarcinoma (aGEA) patients. Here, we tested the association between outcome and EGFR copy number (CN) in pretreatment tissue and plasma cell-free DNA (cfDNA) of patients enrolled in a randomised first-line phase III clinical trial of chemotherapy or chemotherapy plus the anti-EGFR monoclonal antibody panitumumab in aGEA (NCT00824785).

Design

EGFR CN by either fluorescence in situ hybridisation (n=114) or digital-droplet PCR in tissues (n=250) and plasma cfDNAs (n=354) was available for 474 (86%) patients in the intention-to-treat (ITT) population. Tissue and plasma low-pass whole-genome sequencing was used to screen for coamplifications in receptor tyrosine kinases. Interaction between chemotherapy and EGFR inhibitors was modelled in patient-derived organoids (PDOs) from aGEA patients.

Results

EGFR amplification in cfDNA correlated with poor survival in the ITT population and similar trends were observed when the analysis was conducted in tissue and plasma by treatment arm. EGFR inhibition in combination with chemotherapy did not correlate with improved survival, even in patients with significant EGFR CN gains. Addition of anti-EGFR inhibitors to the chemotherapy agent epirubicin in PDOs, resulted in a paradoxical increase in viability and accelerated progression through the cell cycle, associated with p21 and cyclin B1 downregulation and cyclin E1 upregulation, selectively in organoids from EGFR-amplified aGEA.

Conclusion

EGFR CN can be accurately measured in tissue and liquid biopsies and may be used for the selection of aGEA patients. EGFR inhibitors may antagonise the antitumour effect of anthracyclines with important implications for the design of future combinatorial trials.

Significance of this study

What is already known on this subject?

► Clinical trials combining epidermal growth factor receptor (EGFR) inhibitors and chemotherapy for advanced gastro-oesophageal adenocarcinomas (GEAs) have failed in unselected patient populations.
► Anecdotal data suggest that EGFR amplification might predict benefit from EGFR inhibitors in advanced GEA.
► Heterogeneous expression of biomarkers is an intrinsic characteristic of GEA and analysis of liquid biopsies as a tool to overcome intrapatient heterogeneity is warranted.

What are the new findings?

► We tested EGFR copy number in tissue and liquid biopsies from advanced GEA patients enrolled in a prospective randomised phase III trial of chemotherapy alone or chemotherapy plus the anti-EGFR monoclonal antibody panitumumab.
► EGFR status could be reliably detected in tissue and liquid biopsies and concordance between the two was observed in 95% of cases.
► EGFR amplification in tissue and circulating cell-free DNA appeared as a negative prognostic marker in the intention-to-treat population and in individual treatment arms.
► EGFR-amplified cases treated with EGFR inhibitors in combination with chemotherapy had a particularly poor prognosis. Using patient-derived organoids, we showed an antagonistic effect between anti-EGFR agents and the chemotherapy drug epirubicin specifically in EGFR-amplified organoids.

INTRODUCTION
Amplification of receptor tyrosine kinases is a hallmark of gastric and oesophageal adenocarcinomas, with epidermal growth factor receptor (EGFR) amplification occurring in 6%–10% of gastro-oesophageal adenocarcinomas (GEAs).1–3 Although there is level 1 evidence supporting treatment of GEA and breast tumours which harbour amplifications of human epidermal growth factor receptor 2 (HER2) with anti-HER2 therapy, the effect of targeting the EGFR axis in EGFR-amplified tumours is less well established.4–6 Two large randomised trials, REAL3 and EXPAND, evaluated the efficacy of addition of anti-EGFR monoclonal antibodies (mAb) to cytotoxic chemotherapy in patients with unselected, treatment naïve advanced GEA.7 8 Neither trial demonstrated an improvement in survival for anti-EGFR treated patients in a non-biomarker selected patient population. However, emerging translational analyses from unselected clinical trials and new early phase trials in biomarker-defined subgroups suggest that a population of EGFR-amplified GEA might exist who might benefit from anti-EGFR therapy.9 10 If future clinical trials seek to evaluate the efficacy of anti-EGFR therapy in biomarker-enriched populations, understanding the interaction between EGFR amplification and chemotherapy outcome is essential for rational trial design. Additionally, as heterogeneous expression of biomarkers is a fundamental characteristic of gastro-oesophageal cancers, analysis of liquid biopsies as a tool to overcome intrapatient heterogeneity is warranted.10 11

In this study, we tested the association between EGFR amplification and clinical outcome in patients treated with epirubicin, oxaliplatin and capecitabine plus or minus panitumumab (EOX±P) in the REAL3 (randomised trial of EOX with or without panitumumab in Advanced or Locally Advanced Oesophagogastric Cancer 3) Trial (NCT00824785). EGFR status was tested by digital-droplet PCR (ddPCR) and fluorescent in situ hybridisation (FISH) in tumour samples and by ddPCR in plasma samples, and was correlated with progression free survival (PFS) and overall survival (OS) in the trial population. Patient-derived organoids (PDOs) from EGFR-amplified and non-amplified metastatic GEA patients were used for reverse translation in order to study the interaction between chemotherapy and EGFR inhibitors.

METHODS
REAL3 Trial Population
Details of the REAL3 trial have been previously described.8 REAL3 eligible patients had a diagnosis of locally advanced or metastatic oesophagogastric cancer and were treated with EOX (epirubicin, oxaliplatin and capecitabine) plus or minus the fully human monoclonal IgG, anti-EGFR antibody panitumumab. Patients treated with EOX plus panitumumab had inferior OS compared with patients treated with EOX (HR 1.37, 95%CI 1.07 to 1.76; p=0.013). From the REAL3 patient population (n=553), pretreatment tumour biopsies (tissue blocks) with high tumour content (>30%) were selected by a pathologist. All patients included in this analysis had given informed consent for translational research. DNA was extracted from formalin fixed paraffin embedded (FFPE) pretreatment tumour biopsies using QIAamp DNA FFPE (Qiagen, Manchester, UK). Cell-free DNA (cfDNA) was extracted from two ml of patient plasma using the QIAamp DNA Blood Mini Kit (Qiagen, Manchester, UK). cfDNA was eluted in 50 µL of elution buffer and quantified using the Qubit dsDNA HS Assay Kit (Thermo Fisher Scientific, Loughborough, UK).

RESULTS
Study population and EGFR copy number analysis
Of the 553 REAL3 participants, 272 tissue samples from 250 patients and 370 pretreatment cfDNA samples from 354 patients were available for EGFR copy number variation (CNV) analysis either by FISH or ddPCR (figure 1A). In all patients with multiple tissue or cfDNA samples available, a 100% concordance in EGFR CNV was observed across samples.
EGFR CNV FISH data on chemonaive pretreatment tissue (resections or biopsies) were available in 114 out of 200 patients enrolled in the phase II portion of the REAL3 trial; reasons for no availability of results included: (1) lack of patient consent for analysis (n=10); (2) insufficient tumour tissue left following previous analyses (n=36); (3) technical failure (n=18); (4) other reasons for example, block returned to treating hospital (n=22). Of the 114 samples successfully tested, nine patients (7.9%) were found positive for EGFR amplification by FISH.

Using ddPCR, EGFR CNV score on pretreatment tissue was ≥2.0 in 17/250 (6.8%) and ≥5.0 in 12/250 (4.8%) patients. DdPCR EGFR CNV score on pretreatment cfDNA was ≥2.0 in 22/354 (6.2%) and ≥5.0 in 10/354 (2.8%) patients. Overall, cfDNA concentration appeared higher in metastatic compared with locally advanced cancers (p=0.08), while no significant
differences in cfDNA concentration were observed based on gender, localisation of the primary cancer (oesophagus, junction or stomach), or based on presence of lung or peritoneal metastases. A small but significant difference in cfDNA concentration was, however, observed between patients with or without liver metastases (p = 0.007) (online supplemental table 1).

**Comparative EGFR CN analysis in solid and liquid biopsies**

Comparison between EGFR CN determined by FISH and ddPCR on tissue was available in 107 cases, while comparison between EGFR CN determined by ddPCR both on tissue and cfDNA was possible in 170 cases. Finally, comparison among EGFR CN determined by ddPCR on tissue and cfDNA, as well as by FISH on tissue, was available in 60 cases. Overall, EGFR CN status using either FISH, or ddPCR on tissue or cfDNA, was available in 474 patients (85.7% of the ITT population) (figure 1B).

In situ hybridisation is considered the gold standard for the determination of HER2 CN status in breast and gastrooesophageal cancer; we, therefore, used a similar approach for EGFR CN status, and considered FISH as the reference. Concordance between EGFR CN assessed by ddPCR and FISH on tumour tissue was 98%. Compared with FISH, ddPCR showed sensitivity of 1 (95% CI 0.61 to 1.00), specificity of 0.97 (95% CI 0.92 to 0.99), positive predictive value of 0.81 (95% CI 0.47 to 0.96), and negative predictive value of 0.95 (95% CI 0.95 to 1.00) (online supplemental table 2). Next, we compared EGFR CN between matched pretreatment tissue and cfDNA samples, assessed by ddPCR. Overall, concordance was 94.7% (online supplemental table 3); six cases that scored as EGFR-amplified on tissue (3 of them with more than 12 EGFR copies) showed no amplification in cfDNA, while three cases showed EGFR amplification in cfDNA but not on the matched tissue. No significant differences in cfDNA concentration were observed in patients with or without EGFR amplification, suggesting that variable input of cfDNA is unlikely responsible for these discrepancies (online supplemental figure 1). Finally, when EGFR status was tested in the 60 cases for which data by FISH and ddPCR on tissue, and by ddPCR on cfDNA were available, concordance between tissue and blood was 95%: 4 cases scored as EGFR-amplified and 53 cases as EGFR non-amplified by all the three methods, while in 3 cases an EGFR amplification was detected in tissue (by both FISH and ddPCR) but not in cfDNA (online supplemental table 4).

**EGFR CN in tissue and prognosis in the REAL3 trial**

Given the high concordance between EGFR status assessed by FISH and ddPCR on tissue samples, we performed a survival analysis on the 250 patients for whom ddPCR EGFR CN data on tissue were available. Patient characteristics based on EGFR status in each treatment arm are shown in table 1. Patients whose tumours harboured EGFR-amplification (ddPCR CNV score ≥2) had a median PFS of 4.57 months (95% CI 2.5 to 10.56 months), compared with 6.41 months (95% CI 5.99 to 7.34 months) for non-amplified cases (HR 1.30 (95% CI 0.78 to 2.16); p = 0.32); a similar trend was observed when a higher threshold (ddPCR CNV score ≥5) was used for identifying EGFR-amplification (HR 1.70 (95% CI 0.92 to 3.12); p = 0.09) (online supplemental table 5). Similar observations were drawn when the PFS analysis was conducted by treatment arm using both cut-offs (online supplemental table 6). In multivariate analysis adjusting for sex, age, performance status, disease status (locally advanced vs metastatic), and histological subtype, EGFR amplification retained a negative prognostic value regardless of treatment arm (EOX arm HR 1.95 (95% CI 0.5 to 2.9); EOX-P arm HR 1.3 (95% CI 0.7 to 2.5)).

Patients with EGFR-amplified tumours (ddPCR CNV score ≥2) also had a lower median OS of 9.74 months (95% CI 3.68 to 11.35 months), compared with 11.18 months for patients with EGFR non-amplified tumours (95% CI 8.78 to 13.16 months) (HR 1.28 (95% CI 0.57 to 3.01); p = 0.34). A similar trend was observed when a higher cut-off (ddPCR CNV score ≥5) was applied in order to identify EGFR amplification (HR 1.5 (95% CI 0.82 to 2.78); p = 0.47) (online supplemental table 7). Analogous results were observed when the OS analysis was conducted by treatment arm for both cut-offs (online supplemental table 8).
Given the small number of EGFR-amplified cases in our trial cohort limited the statistical power of the analysis, we sought to validate our findings in an independent cohort of GEA. We screened the cBioportal for Cancer Genomics for localised and metastatic GEA cases for whom EGFR amplification status was available. Our search returned data on 2122 samples from 2054 patients (online supplemental figure 2A) across 11 non-overlapping studies. In line with our findings, EGFR amplification was observed in approximately 6.5% of patients and was consistently associated with inferior OS, disease-specific survival, disease-free survival and PFS (online supplemental figure 2B–E) in the validation cohorts. Taken together these data strengthen the notion that EGFR-amplification may be a prognostic biomarker in GEA.

Table 1 Patient characteristics by treatment arm and EGFR status determined on tumour tissue (n=250)

<table>
<thead>
<tr>
<th></th>
<th>EOX arm</th>
<th></th>
<th>EOX-P arm</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EGFR non-amplified (&lt;2)</td>
<td>EGFR amplified (≥2)</td>
<td>EGFR non-amplified (&lt;2)</td>
</tr>
<tr>
<td>Median age (IQR)</td>
<td>62.6 (54.2–68.4)</td>
<td>63.8 (54.3–68.6)</td>
<td>63.2 (56.6–69.7)</td>
</tr>
<tr>
<td>Males (%)</td>
<td>97 (80.8)</td>
<td>7 (100)</td>
<td>89 (78.8)</td>
</tr>
<tr>
<td>Females (%)</td>
<td>23 (19.2)</td>
<td>–</td>
<td>24 (21.2)</td>
</tr>
<tr>
<td>PS 0 (%)</td>
<td>44 (36.7)</td>
<td>4 (57.1)</td>
<td>42 (37.2)</td>
</tr>
<tr>
<td>PS 1 (%)</td>
<td>69 (57.5)</td>
<td>2 (28.6)</td>
<td>65 (57.5)</td>
</tr>
<tr>
<td>PS 2 (%)</td>
<td>7 (5.8)</td>
<td>1 (14.3)</td>
<td>6 (5.3)</td>
</tr>
<tr>
<td>Locally advanced (%)</td>
<td>8 (6.7)</td>
<td>–</td>
<td>10 (8.9)</td>
</tr>
<tr>
<td>Metastatic (%)</td>
<td>112 (93.3)</td>
<td>7 (100)</td>
<td>103 (91.1)</td>
</tr>
</tbody>
</table>

EGFR, epidermal growth factor receptor; EOX, epirubicin, oxaliplatin, capecitabine; P, panitumumab; PS, performance status.

Table 2 Patients characteristics by treatment arm and EGFR status determined on cfDNA (n=354)

<table>
<thead>
<tr>
<th></th>
<th>EOX arm</th>
<th></th>
<th>EOX-P arm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age (IQR)</td>
<td>62.8 (56.1–68.3)</td>
<td>60.8 (49.8–65.3)</td>
<td>63.4 (55.8–69.9)</td>
</tr>
<tr>
<td>Males (%)</td>
<td>139 (85.3)</td>
<td>3 (75)</td>
<td>138 (81.7)</td>
</tr>
<tr>
<td>Females (%)</td>
<td>24 (14.7)</td>
<td>1 (25)</td>
<td>31 (18.3)</td>
</tr>
<tr>
<td>PS 0 (%)</td>
<td>70 (42.9)</td>
<td>2 (50)</td>
<td>77 (45.6)</td>
</tr>
<tr>
<td>PS 1 (%)</td>
<td>82 (50.3)</td>
<td>2 (50)</td>
<td>85 (50.30)</td>
</tr>
<tr>
<td>PS 2 (%)</td>
<td>11 (6.8)</td>
<td>–</td>
<td>7 (4.1)</td>
</tr>
<tr>
<td>Locally advanced (%)</td>
<td>20 (12.3)</td>
<td>–</td>
<td>26 (15.4)</td>
</tr>
<tr>
<td>Metastatic (%)</td>
<td>143 (87.7)</td>
<td>4 (100)</td>
<td>143 (84.6)</td>
</tr>
</tbody>
</table>

cfDNA, cell-free DNA; EGFR, epidermal growth factor receptor; EOX, epirubicin, oxaliplatin, capecitabine; P, panitumumab; PS, performance status.
WGS ($r^2:0.82; p:0.003$) for both tissue and plasma cfDNA. 70% of patients had coamplifications of receptor tyrosine kinase or other cancer-promoting genes, including MET, KRAS, FGFR1, IGFR1, SRC and VEGFA, potentially associated with resistance to EGFR-inhibitors (figure 3C). Interestingly, the VEGFA amplification was not detected in the tissue but only in plasma for PT23 (online supplemental figure 4). Taken together, these data suggest that some of the partial responses and favourable outcomes observed in EGFR-amplified cases treated with EOX-P were probably driven by the EOX chemotherapy backbone alone rather than by EGFRi.

Inferior outcome in GEA patients treated with panitumumab in combination with an epirubicin-containing chemotherapy regimen compared with chemotherapy alone, has also been reported by the AIO/CAO STO-0801 trial. Interestingly, a similar detriment was not observed in the EXPAND trial that investigated the addition of the anti-EGFR mAb cetuximab in a comparable chemotherapy backbone that excluded the anthracycline component. Indeed, multiple lines of evidence suggest that anti-EGFR agents may be effective when combined with fluoropyrimidines and platinum compounds for the treatment of metastatic GEA cancers, but evidence advocating their combination with anthracyclines are lacking and, if anything, point towards the opposite outcome in GEA patients treated with panitumumab in combination with anthracycline-containing chemotherapy compared with chemotherapy alone. Hence, multiple lines of evidence suggest that the combinatorial treatment did induce a notable downregulation of cyclin E1 (encoded by CDKN1A) and the M phase-related cyclin B1 (encoded by CCNB1; figure 4C). Protein expression analysis of EGFR-amplified and non-amplified PDOs treated with epirubicin alone or in combination with cetuximab confirmed that the combinatorial treatment did induce a notable downregulation of both p21 and cyclin B1 proteins selectively in the former, coupled with increased levels of the S phase-promoting cyclin E1 (figure 4D). These data suggested that inhibition of EGFR signalling in an anthracycline treatment background may have a cell cycle-promoting effect in EGFR-amplified but not in EGFR-non-amplified gastric cancer cells. Indeed, the acceleration of cell cycle on the addition of cetuximab selectively in epirubicin-treated EGFR-amplified gastric cancer PDOs was further confirmed using a thymidine analog-based DNA incorporation FACS assay (figure 4E).

First, we modelled clinical observations reported in EGFR-amplified GEA patients treated with single agent EGFRi (EGFRi), in EGFR-amplified PDOs from metastatic gastro-oesophageal cancers (figure 4A) and we showed a significant effect on cell viability on treatment with single-agent anti-EGFR small molecule gefitinib and, to a lesser extent, with the anti-EGFR mAb cetuximab (online supplemental figure 5A).

Next, we combined EGFRi with clinically relevant concentrations of epirubicin and we observed a consistent increase in cell viability selectively in EGFR-amplified PDOs, but not in EGFR diploid PDOs (figure 4B and online supplemental figure 5B) or cell lines (online supplemental figure 6). In line with this, pathway analysis of RNA-seq data (online supplemental tables 16 and 17, online supplemental figure 7) from EGFR-amplified PDOs treated with epirubicin alone or in combination with cetuximab, showed that the combination of the anthracycline and the anti-EGFR agent significantly downregulated several cell cycle-related genes, including the G1/S negative regulator p21 (encoded by CDKN1A) and the M phase-related cyclin B1 (encoded by CCNB1; figure 4C). Protein expression analysis of EGFR-amplified and non-amplified PDOs treated with epirubicin alone or in combination with cetuximab confirmed that the combinatorial treatment did induce a notable downregulation of both p21 and cyclin B1 proteins selectively in the former, coupled with increased levels of the S phase-promoting cyclin E1 (figure 4D). These data suggested that inhibition of EGFR signalling in an anthracycline treatment background may have a cell cycle-promoting effect in EGFR-amplified but not in EGFR-non-amplified gastric cancer cells. Indeed, the acceleration of cell cycle on the addition of cetuximab selectively in epirubicin-treated EGFR-amplified gastric cancer PDOs was further confirmed using a thymidine analog-based DNA incorporation FACS assay (figure 4E).
Figure 3  Clinical outcome by treatment arm in EGFR-amplified cases enrolled in the REAL3 trial. (A) Bars show OS and PFS (median±SE) in EGFR-amplified patients treated with chemotherapy alone (EOX) or chemotherapy plus panitumumab (EOX-P). Similar trends are observed when a cut-off of two or five EGFR copies is used. (B) Blue bars indicate PFS, orange bars indicate EGFR copies determined by ddPCR in plasma cfDNA (graph on the top) or tissue (bottom). (C) Plots show copy number changes in EGFR (blue) and other receptor tyrosine kinase genes (red) in patients with PFS greater than 6 months on treatment with EOX-P. Values outside of the y-axis limits are plotted at the limit. cfDNA, cell-free DNA; CN, copy number; ddPCR, digital-droplet PCR; EGFR, epidermal growth factor receptor; EOX, epirubicin+oxaliplatin+capecitabine; OS, overall survival; P, panitumumab; PFS, progression-free survival.
Figure 4  Effect of epirubicin or epirubicin plus EGFR inhibitors in EGFR-amplified and non-amplified patient-derived organoids. (A) EGFR FISH images, demonstrating gain of copies and diploid status in the F-014 BL and DD191 human GEA PDO lines, respectively. (B) Concentration-dependent effect of epirubicin as a monotherapy or in combination with a stable dose of two different anti-EGFR agents (cetuximab, 20 µg/mL; gefitinib, 200 nM) in the EGFR-amplified F-014 BL and EGFR-diploid DD191 human GEA PDO lines. The combination of low epirubicin concentrations with anti-EGFR treatments results in a paradoxical increase in viability selectively in the EGFR-amplified F-014 BL GEA PDO line. Viability data shown are means±SEM of indicated independent experiments. (C) Pathway analysis of RNAseq data from the EGFR-amplified F-014 BL GEA PDO line treated with a low concentration of epirubicin alone or in combination with cetuximab for 24 hours revealed a significant reduction in the expression of cell cycle-related genes associated with the epirubicin and cetuximab combination. RNA from three independent biological replicates were sequenced per condition. (D) Protein analysis of the EGFR-amplified F-014 BL and EGFR-diploid DD191 human GEA PDO lines treated with two low concentrations of epirubicin alone or in combination with cetuximab for 24 hours. In line with RNAseq data, a reduction in p21 and cyclin B1 protein levels was observed when epirubicin was combined with inhibition of EGFR and downstream MAPK and AKT signalling specifically in the EGFR-amplified organoid line. (E) EdU DNA incorporation assay following treatment of the EGFR-amplified F-014 BL and EGFR-diploid DD191 human GEA PDO lines with two low concentrations of epirubicin alone or in combination with cetuximab for 24 hours. The addition of cetuximab antagonises the antiproliferative effect of epirubicin and accelerates DNA synthesis specifically in the EGFR-amplified organoid line. (F) Proposed model of antagonism between epirubicin and anti-EGFR treatments in EGFR-amplified GEA. EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridisation; FSC-A, forward scatter-area; GEA, gastro-oesophageal adenocarcinoma; KEGG, Kyoto Encyclopedia of Genes and Genomes; PDO, patient-derived organoid.
increase in proliferation observed in the EGFR-amplified PDOs in response to the epirubicin and anti-EGFR combinatorial treatment. Interestingly, cetuximab, both as a single agent and in combination with epirubicin, increased EGFR protein stability, leading to increased EGFR nuclear localisation; however, this cetuximab-mediated increase of nuclear EGFR was observed in both PDOs regardless of their EGFR CN status (online supplementary figure 8).

Taken together, our observations suggest that inhibition of EGFR signalling in a background of epirubicin treatment selectively induces the downregulation of the G1/S negative regulator p21 and the upregulation of the S phase-promoting cyclin E1 in EGFR-amplified gastric cancer PDOs, thereby leading to increased flux to the S phase of the cell cycle. Cyclin E1 upregulation has been linked to shortened mitosis and increased mitotic exit.\(^{23}\) These observations, together with decreased levels of M phase-associated proteins observed when epirubicin is combined with cetuximab (figure 4D), suggest that inhibition of EGFR in a background of epirubicin treatment may also speed up the M-to-G1 transition in EGFR-amplified PDOs, thereby leading to an overall accelerated progression through the cell cycle (figure 4F). Increased nuclear localisation of EGFR was observed in cells treated with the combination of epirubicin and cetuximab irrespective of EGFR status and, this phenomenon, might partially explain the detrimental effect caused by the addition to panitumumab to EOX in the REAL3 trial population. The activation of additional cotranscriptional factors in EGFR-amplified cases might account for the paradoxical effect observed specifically in this subgroup of patients.

### DISCUSSION

In this study, using ddPCR performed on routine diagnostic biopsies obtained from oesophagogastric cancer patients treated in the REAL3 trial, we identify a 7% prevalence of patients with EGFR-amplified tumours, which is consistent with the literature.\(^{1-3}\) We demonstrate that EGFR analysis in plasma is complementary to EGFR amplification detection in tumour tissue, and EGFR amplification appears associated with poor prognosis, even though these data are not statistically significant likely due to the small number of EGFR-amplified cases. Our results also suggest that EGFR-amplified tumours did not benefit from anti-EGFR therapy in combination with chemotherapy; in fact, both our clinical and preclinical data suggest an antagonistic effect between anthracyclines and anti-EGFR, with potential implications for the design of future drug combination trials.

EGFR amplification is observed in 6%-10% of gastric and gastro-oesophageal cancers across multiple datasets, and is recognised as negatively prognostic in surgically treated patients.\(^{26-28}\) However, the association between EGFR amplification and outcome in patients with metastatic gastro-oesophageal cancer treated with cytotoxic chemotherapy in the context of a clinical trial has not been previously described. In the perioperative phase II randomised AIO/CAO STO-0801 trial assessing the addition of panitumumab to perioperative epirubicin, cisplatin and capecitabine chemotherapy in unselected patients with resectable gastro-oesophageal cancer, both EGFR overexpression or gene amplification were negatively prognostic for survival, independent of treatment arm.\(^{31}\) Interestingly, the HR for OS in AIO/CAO STO-0801 which used an almost identical chemotherapy regimen (ECX) and the same anti-EGFR therapy as REAL3 (panitumumab) was strikingly similar to the REAL3 results (ECX-P vs ECX HR 1.37, 95% CI 0.84 to 2.25, p=0.2). However, this result lacks statistical power due to the relatively modest size of the AIO/CAO STO-0801 trial (n=160). Notably, the EXPAND trial which investigated the addition of cetuximab to cisplatin and fluoropyrimidine chemotherapy did not use an anthracycline and did not demonstrate a significant detriment to anti-EGFR therapy.\(^{7}\) Furthermore, in EXPAND patients with the highest levels of EGFR protein expression appeared to have an increased benefit from cetuximab.\(^{29}\) Although our data and the retrospective analyses of AIO/CAO STO-0801 and EXPAND trials are based on small numbers of patients with EGFR-amplified cancers, they are provocative as, taken together, suggest a negative interaction between anti-EGFR therapy and anthracyclines in EGFR-amplified GEA.

Although first generation anti-EGFR trials in unselected GEA patients were negative, hints regarding the potential efficacy of anti-EGFR therapy in biomarker-selected populations have recently emerged in the literature.\(^{2,9,30}\) For example, although the COG study of gefitinib compared with best supportive care in unselected previously treated oesophageal cancer patients did not show a benefit in survival for gefitinib, post hoc biomarker analysis using FISH for EGFR CN has suggested a significant survival benefit for EGFR-amplified tumours (OS benefit for gefitinib in EGFR-amplified HR=0.21, 95% CI 0.07 to 0.64; p=0.006)\(^{9,11,30}\) Similarly, in a study evaluating multiple EGFR inhibitors including ABT-806 and cetuximab in EGFR-amplified gastro-oesophageal cancers, several profound responses to single agent anti-EGFR therapy were observed (objective response rate 57%) and the median PFS for patients treated with anti-EGFR therapy alone and in combination was 10 months\(^{2}\) and largely surpassed the benefits of standard cytotoxic chemotherapy in gastro-oesophageal cancer.

Heterogeneity of biomarker expression is common in gastro-oesophageal cancer, and can impact significantly on the efficacy of targeted therapy and trial results.\(^{10,31,32}\) It is possible that ctDNA sampling may overcome some of the challenges associated with tissue heterogeneity as we have previously shown in colorectal cancer,\(^{33}\) however, ctDNA may not be present in all gastro-oesophageal cancer patients as its load relates to tumour burden.\(^{34}\) In keeping with this observation, higher ctDNA concentrations were observed in metastatic compared with locally advanced patients in our analysis. Detection of gene amplification in plasma has been suggested to be prognostic for targeting HER2 and FGFR2-amplified gastro-oesophageal tumours\(^{31,35}\) and screening for multiple simultaneous amplifications might have important implications. 70% of EGFR-amplified patients tested by WGS in our study showed coamplifications that can be therapeutically exploited and therapeutic targeting in biomarker-selected patients is feasible.\(^{36}\)

The optimal cut-off for sensitivity to anti-EGFR therapy and the value of targeting this axis in EGFR-amplified gastro-oesophageal cancer have not yet been fully delineated: Maron et al observed responses to anti-EGFR therapy in patients with EGFR CN over the 50th percentile (2.4 copies in plasma).\(^{5}\) However, it is plausible that higher levels of EGFR amplification (and as such oncogene addiction) could enrich future trials for patients more likely to respond to anti-EGFR therapy.

A potential limitation of this study is that approximately half of REAL3 tumours had tissue available for amplification.
testing as many samples were used in previous biomarker studies.\textsuperscript{36,37} Specifically, small numbers of \textit{EGFR}-amplified cases were included in the survival analyses limiting the power of this work. That being said, it is worth considering that: (1) the prognostic trend for \textit{EGFR} amplification was also confirmed in liquid biopsies (available for 63\% of the ITT cohort) and 200 patients in this analysis did not overlap with those presented for tissue analysis and (2) in multivariate analyses, the effect of \textit{EGFR} amplification on survival appeared to be consistent when adjusted for potential confounders. The second potential limitation of our study is the a priori difference in chemotherapy dose and in survival between the arms of the trial. Patients treated in the EOX-P arm of REAL3 received a dose reduction of oxaliplatin and cetuximab in metastatic colorectal cancer patients.\textsuperscript{38–40} The observation that a reduction in reactive oxygen species in response to cetuximab treatment can impair oxaliplatin-induced apoptosis provides a biological explanation for these clinical observations.\textsuperscript{41} Whether this hypothesis contributes to explain the inferior outcome observed in EOX-P treated patients in the REAL3 trial remains to be confirmed. However, given durable responses to FOLFOX+ cetuximab have been observed in \textit{EGFR}-amplified metastatic gastro-oesophageal cancer patients\textsuperscript{3} and chemotherapy regimens containing anthracyclines in combination with panitumumab have been consistently associated with panitumumab have been consistently associated with lower survival in \textit{EGFR}-amplified tumours.\textsuperscript{42} We focused our preclinical analysis on the antagonism between \textit{epirubicin} and \textit{EGFR}i.

In conclusion, herein, we present results that suggest that \textit{EGFR} status can be measured using ddPCR in tumour and plasma in a cost-effective way and that \textit{EGFR} amplification is associated with a negative survival outcome in patients with GEA independent of treatment arm. Our results also emphasise the challenge in designing optimal drug combinations in absence of robust patient-centred preclinical models. In view of the relatively rarity of \textit{EGFR}-amplified gastro-oesophageal cancers, we suggest that international collaborative efforts may be required in order to facilitate prospective trials enriched for \textit{EGFR}-amplified tumours based on liquid biopsy testing.

\textbf{Author affiliations}

1Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
2Department of Medicine, Royal Marsden Hospital NHS Trust, London, UK
3Molecular Pathology, The Institute of Cancer Research, Sutton, UK
4Centre for Evolution and Cancer, The Institute of Cancer Research, Sutton, UK
5Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK
6Clinical Research & Development, Royal Marsden Hospital NHS Trust, London, UK
7Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Dresden, Germany
8Department of Medical Oncology, Christie Hospital, Manchester, UK
9Department of Clinical Oncology, Velindre Cancer Centre, Cardiff, UK
10Cancer Clinical Trials Centre, Weston Park Cancer Centre, Sheffield, UK
11Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
12Department of Medicine (DIMED), University of Padua, Padova, Italy
13Histopathology, Royal Marsden Hospital NHS Trust, London, UK
14Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
15German Cancer Consortium (DKTK), Partner Site Dresden, Heidelberg, Germany
16National Center for Tumor Diseases, Partner Site Dresden, Heidelberg, Germany

\textbf{Twitter} Igor Vivanco \copyright IgorTheBioGuy

\textbf{Contributors} DC, DW, SR, NS, TW, AQ, TC, WM, JW, GM and IC recruited patients in the trial. GV, SH, AH, SH, MS, JF-M, GDC, EF, TS, JH, AL, MF, CB, IV, AS and DES performed experiments. KK and CP performed statistical analyses. RB coordinated tissue collection, AW performed histopathology review. ES, DC and NV conceived the analysis and wrote the experimental protocol. ES, GV and NV wrote the manuscript. All the authors reviewed and approved the manuscript.

\textbf{Funding} This work was supported by Cancer Research UK (grant numbers A18052 and A22909), the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research (grant numbers A62, A100, A101, A159) and the European Union FP7 (grant number CIG 334261) to NV. AS is supported by the Wellcome Trust (202778/B/16/2) and Cancer Research UK (A22909). This work was also supported by funding from the National Institute of Health (NCI US5 CA217376) to AS, and from a Wellcome Trust award to the Centre for Evolution and Cancer (105104/Z/14/Z). The authors acknowledge support from the National Institute for Health Research Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research.

\textbf{Competing interests} ES declares honoraria for advisory role from Astellas, BMS, Celgene, Five Prime, Grifols Oncology, and Servier. DW has received honoraria from Amgen. NS received research funding from AstraZeneca, Pfizer, BMS and honoraria from Servier, MSD, Merck Serono and AstraZeneca. JW received honoraria from Eisai, AstraZeneca, Sanofi-Genzyme, Ipsen, Novartis, Bayer, Celgene and Advanced Accelerator Applications. IC has had advisory roles with Merck Serono, Roche, Sanofi Oncology, Bristol Myers Squibb, Eli-Lilly, Novartis, Roche and Sanofi Oncology, and honoraria from Roche, Sanofi-Oncology, Eli-Lilly, Taiho, Bayer and Prime Therapeutics. IV has received honoraria from AbbVie. He has received research funding from Genmab and Baselica. DC received research funding from 4SC, AstraZeneca, Bayer, Celgene, Clovis, Eli-Lilly, Janssen, Medimmune, Merck, Merrimack, Amgen, Sanofi. NV received honoraria from Merck Serono, Pfizer, Bayer and Eli-Lilly. All other authors declare no conflict of interest.

\textbf{Patient consent for publication} Not required.

\textbf{Provenance and peer review} Not commissioned; externally peer reviewed.

\textbf{Data availability statement} All data relevant to the study are included in the article or uploaded as online supplemental information. RNA-Seq and WGS data are reported in the online supplemental tables.

\textbf{Supplemental material} This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

\textbf{Open access} This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the license is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

\textbf{ORCID iDs}

Georgios Vlachogiannis http://orcid.org/0000-0003-3114-8772
George D Cresswell http://orcid.org/0000-0003-3303-068X
Daniel E Stange http://orcid.org/0000-0003-4246-2230
Nicolia Valeri http://orcid.org/0000-0002-5426-5683

\textbf{REFERENCES}


Copyright © 2023 BMJ Publishing Group Ltd.


